Skip to Main content Skip to Navigation

Radiothérapie adaptative morphologique et métabolique des cancers ORL

Abstract : Objectifs: The aims of this work were (i) to evaluate the dosimetric benefit and to predict the clinical benefit of adaptive radiotherapy for head and neck cancer, regarding both toxicities and local control, (ii) to identify patients whose good candidate for an adaptive strategy, and (iii) to identify the best adaptive strategy to spare the parotid glands. Materials and methods: The dosimetric benefit was assessed using data from a phase III study evaluating the clinical benefit of an adaptive radiotherapy. Cumulated dose with and without adaptive was estimated using deformable image registration. Different methods of deformable image registration were evaluated regarding both spatial and dose estimation accuracy. Predictive model of the risk of parotid gland overdose was computed using generalized linear mixed model and cross validation by leave‐one‐out. The dosimetric benefit of numerous replanning strategies, defined by various numbers and timing of replanning, with regard to parotid gland sparing, was quantified. We performed a systematic review to evaluate the predictive value of quantitative PET parameters. The predictive value of PET intensity parameters was assessed using two independent cohorts of patients. Résultats: Without adaptive radiotherapy, 65% of the patients had a PG overdose of more than 2 Gy and 50% of the patients had a tumor underdose of more than 1 Gy. Adaptive radiotherapy allows to correct both parotid gland overdose and tumor underdose. Based on parameters calculated at the planning and at the first week of treatment, predictive models of PG overdose and tumor underdose were computed. PET parameters correlated with overall survival were identified. Using two independent cohorts of patients, a nomogram to predict survival was build and externally validated. Conclusion: Our studies showed the benefit of adaptive radiotherapy to spare the parotid glands while increasing tumor coverage. These benefits should allow to decrease the toxicities while increasing local control. Early anatomical and dosimetric parameters allow identifying patients at risk of tumor underdose or parotid gland overdose. PET performed before the treatment allows identifying patients with a high‐risk of locoregional failure and death, potentially candidates for treatment. These results justify further studies on a larger cohort of patients, ideally in phase III clinical trials.
Document type :
Complete list of metadata

Cited literature [239 references]  Display  Hide  Download
Contributor : ABES STAR :  Contact
Submitted on : Friday, May 4, 2018 - 12:29:05 PM
Last modification on : Wednesday, September 14, 2022 - 10:20:04 AM
Long-term archiving on: : Tuesday, September 25, 2018 - 12:03:13 PM


Version validated by the jury (STAR)


  • HAL Id : tel-01785379, version 1


Joël Castelli. Radiothérapie adaptative morphologique et métabolique des cancers ORL. Médecine humaine et pathologie. Université Rennes 1, 2017. Français. ⟨NNT : 2017REN1B043⟩. ⟨tel-01785379⟩



Record views


Files downloads